|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 22:33
|
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire)
|
|
|
DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment; Interim Analysis planned in 4Q 2026
$51.3 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027
Conference Call and Webcast on May 7 at 8:00 AM ET / 7:00 AM CT
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference call on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the Company's business update and first quarter 2026 financial results.
“We continue to focus on moving our clinical programs forward. Looking ahe...
|
|
|
06.05.26 - 22:18
|
Tronox Reports First Quarter 2026 Financial Results (PR Newswire)
|
|
|
STAMFORD, Conn., May 6, 2026 /PRNewswire/ -- Tronox Holdings plc (NYSE:TROX) ("Tronox" or the "Company"), the world's leading integrated manufacturer of titanium dioxide ("TiO2") pigment, today reported its financial results for the quarter ending March 31, 2026, as follows: First Quarter......
|
|
|
|
|
06.05.26 - 22:09
|
Aeva Reports First Quarter 2026 Results (Business Wire)
|
|
|
Achieved New Record Quarterly Revenue with Growing Commercial Momentum
Key Milestones Achieved in Automotive and Commercial Vehicles with Production Intent Atlas Sensors Delivered to Daimler Truck and Atlas Ultra Integration with Top European Passenger OEM
Additional Commercial Deployments in Physical AI with Forterra in Defense, Aeva CityOS in ITS and Nikon in Factory AutomationMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, today announced its first quarter 2026 results.
Key Company Highlights
Delivered production intent Atlas sensors to Daimler Truck, highlighting the maturity of Aeva's technology and a major step to bringing the OEM's autonomous trucks to production
Delivered first Atlas Ultra sensors to the Top 10 European passenger OEM for vehicle integration and AV stack development
Working with NVIDIA on integrating 4D LiDAR as the reference sensor for the DRIVE Hyperion platform used by leading OEMs and AV companies to e...
|
|
|
06.05.26 - 22:03
|
Xencor Reports First Quarter 2026 Financial Results (Business Wire)
|
|
|
-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 --
-- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start --
-- Plamotamab and XmAb657 autoimmune studies on-track for 2H26 progress update --PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.
“Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for the treatment of advanced clear cell renal cell carcinoma at a medical meeting in the second half of 2026, which will help support the initiation of our first pivotal study planned for 2027,” said Bassil Dahiyat, P...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 19:18
|
Director/PDMR Shareholding (Cision)
|
|
|
ZIGUP plc
("ZIGUP" or the "Company")
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES OR CONNECTED PERSONS
The Company announces the vesting on 1 May 2026 of nil cost options granted to Rachel Coulson, Chief Financial Officer under the ZIGUP PLC Long-Term Incentive Plan (“LTIP”).
The options were awarded on 20 August 2025 as part of her remuneration arrangements on appointment as Chief Financial Officer.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
+--+-...
|
|
Alle News zu Großbritannien 10450.3555 +1.78% (FTSE 100 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
